The community of microorganisms that colonise the mucosal surfaces of our body, such as the gastrointestinal tract, respiratory tract, genitourinary tract, and even the ocular surface, plays a pivotal role in maintaining our health. This effect results from complex interactions between commensals and host cells at several levels, including the direct effects of commensals against pathogens, the training of immunocytes locally or at distance from the mucosal surfaces and the generation of a wide variety of molecules from the metabolization of food components. These molecules are subsequently important for host cells of different systems. Nonetheless, antibiotics often exhibit a broad range of activity that does not differentiate between harmful pathogens and beneficial microbiota.
This indiscriminate action can disrupt the balanced composition of the mucosal microbiota, leading to an incident known as dysbiosis. Dysbiosis is linked to several health problems, including chronic inflammatory conditions, metabolic disorders, and paradoxically, could also increase vulnerability to infections.
This research topic aims to investigate the impact of antibiotic therapies on the microbiotas of different mucosal surfaces and how they are linked to different pathologies. Such alterations represent the final endpoint of altered molecular pathways that involve molecules derived from both the host and the microorganisms. However, these pathways are far from well-known. Therefore, improving our understanding of the effects of antibiotic use on commensal microbiotas from different mucosas, by analyzing these effects at molecular and/or clinical levels using state-of-the-art methodologies should shed new light on the correction of dysbiosis associated to different conditions. Therefore, the focus is on the negative effects of antibiotic-induced dysbiosis on health, considering which microbial species are more susceptible to antibiotics, and exploring ways to prevent or reduce dysbiosis by using alternative treatments as probiotics or fecal microbiota transplantation.
Understanding the relationship between antibiotics and mucosal microbiota is of immense significance. This topic brings together various fields, including clinical practice, microbiology, immunology, pharmacology, and public health policy, to shed light on the complex interplay between antibiotics and mucosal microbiota. By comprehending this interaction, we can develop better therapeutic strategies to combat antibiotic resistance and promote optimal health. Manuscripts exploring these themes in any mucosal tissue, whether conducted in human subjects or animal models are welcome. Of particular interest are studies presenting data on antibiotic effects on the microbiota resistome, human and/or microbial metabolomes, and/or the immune response. Contributions can take the form of Original Research articles, Mini-Reviews, Case Reports, Clinical Trials and Brief-Research Reports.
Keywords:
antibiotics, microbiome, disbiosis, intestinal microbiome, therapeutics, drugs
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
The community of microorganisms that colonise the mucosal surfaces of our body, such as the gastrointestinal tract, respiratory tract, genitourinary tract, and even the ocular surface, plays a pivotal role in maintaining our health. This effect results from complex interactions between commensals and host cells at several levels, including the direct effects of commensals against pathogens, the training of immunocytes locally or at distance from the mucosal surfaces and the generation of a wide variety of molecules from the metabolization of food components. These molecules are subsequently important for host cells of different systems. Nonetheless, antibiotics often exhibit a broad range of activity that does not differentiate between harmful pathogens and beneficial microbiota.
This indiscriminate action can disrupt the balanced composition of the mucosal microbiota, leading to an incident known as dysbiosis. Dysbiosis is linked to several health problems, including chronic inflammatory conditions, metabolic disorders, and paradoxically, could also increase vulnerability to infections.
This research topic aims to investigate the impact of antibiotic therapies on the microbiotas of different mucosal surfaces and how they are linked to different pathologies. Such alterations represent the final endpoint of altered molecular pathways that involve molecules derived from both the host and the microorganisms. However, these pathways are far from well-known. Therefore, improving our understanding of the effects of antibiotic use on commensal microbiotas from different mucosas, by analyzing these effects at molecular and/or clinical levels using state-of-the-art methodologies should shed new light on the correction of dysbiosis associated to different conditions. Therefore, the focus is on the negative effects of antibiotic-induced dysbiosis on health, considering which microbial species are more susceptible to antibiotics, and exploring ways to prevent or reduce dysbiosis by using alternative treatments as probiotics or fecal microbiota transplantation.
Understanding the relationship between antibiotics and mucosal microbiota is of immense significance. This topic brings together various fields, including clinical practice, microbiology, immunology, pharmacology, and public health policy, to shed light on the complex interplay between antibiotics and mucosal microbiota. By comprehending this interaction, we can develop better therapeutic strategies to combat antibiotic resistance and promote optimal health. Manuscripts exploring these themes in any mucosal tissue, whether conducted in human subjects or animal models are welcome. Of particular interest are studies presenting data on antibiotic effects on the microbiota resistome, human and/or microbial metabolomes, and/or the immune response. Contributions can take the form of Original Research articles, Mini-Reviews, Case Reports, Clinical Trials and Brief-Research Reports.
Keywords:
antibiotics, microbiome, disbiosis, intestinal microbiome, therapeutics, drugs
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.